New drug combo aims to wipe out leukemia without chemo
NCT ID NCT04747912
First seen Apr 01, 2026 · Last updated May 13, 2026 · Updated 5 times
Summary
This study tests adding the drug inotuzumab ozogamicin (InO) to standard treatment for adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this chemotherapy-free approach leads to faster and deeper remission, where no cancer cells are detectable. About 25 participants will receive the combination and be monitored for response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago Medical Center
Chicago, Illinois, 60615, United States
Conditions
Explore the condition pages connected to this study.